Author:
Day Richard O.,Graham Garry G.,Williams Kenneth
Reference13 articles.
1. Bishay, P., Schmidt, H., Marian, C., Haussler, A., Wijnvoord, N., Ziebell, S., et al. (2010). R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS ONE, 5(5), e10628.
2. Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., et al. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New England Journal of Medicine, 345(25), 1809–1817.
3. CNT, & Coxib and traditional NSAID Trialists’ (CNT) Collaboration. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet. doi:10.1016/S0140-6736(1013)60900-60909.
4. Duggan, K. C., Hermanson, D. J., Musee, J., Prusakiewicz, J. J., Scheib, J. L., Carter, B. D., et al. (2011). (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nature Chemical Biology, 7(11), 803–809.
5. Graham, G. G., & Williams, K. M. (2004). Metabolism and pharmacokinetics of ibuprofen. In K. D. Rainsford (Ed.), Aspirin and related drugs (pp. 157–180). London: Taylor & Francis.